Medivation to Host Teleconference on January 30, 2014 to Discuss Final Results From the Phase 3 PREVAIL Trial

Medivation to Host Teleconference on January 30, 2014 to Discuss Final Results 
From the Phase 3 PREVAIL Trial 
SAN FRANCISCO, CA -- (Marketwired) -- 01/28/14 --  Medivation, Inc.
(NASDAQ: MDVN) today announced that it will host a live
teleconference with management to discuss the final results from the
Phase 3 PREVAIL trial on January 30, 2014 at 1:30 pm Pacific Time.
Dr. Tomasz M. Beer, M.D., F.A.C.P., professor of medicine and deputy
director of the Knight Cancer Institute at Oregon Health & Science
University, and co-principal investigator of the PREVAIL study will
participate in the call. 
Interested parties may listen to the live teleconference by calling
877-303-2523 from the U.S. or +1-253-237-1755 internationally.
Individuals may access the live audio webcast by visiting:
http://investors.medivation.com/events.cfm.  
About Medivation  
Medivation, Inc. is a biopharmaceutical company focused on the rapid
development of novel therapies to treat serious diseases for which
there are limited treatment options. Medivation aims to transform the
treatment of these diseases and offer hope to critically ill patients
and their families. For more information, please visit us at
www.medivation.com. 
Contacts:
Patrick Machado 
Chief Business & Financial Officer 
(415) 829-4101  
Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900 
 
 
Press spacebar to pause and continue. Press esc to stop.